A pivotal Phase 3 clinical trial program for NNZ-2591 to treat children with Phelan-McDermid syndrome (Telomeric-22q13-Monosomy-Syndrome)
Latest Information Update: 23 Apr 2025
At a glance
- Drugs NNZ 2591 (Primary)
- Indications Telomeric 22q13 Monosomy Syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Neuren Pharmaceuticals
- 14 Apr 2025 According to Neuren Pharmaceuticals media release, the company plans to commence the Phase 3 trial in the mid of 2025, subject to FDA review of the final version of the trial protocol.
- 14 Apr 2025 According to Neuren Pharmaceuticals media release, primary endpoints for this trial have been confirmed at a productive Type C Meeting with the US Food and Drug Administration (FDA).
- 25 Feb 2025 New trial record